The Top 50 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market Report 2022: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
The pharmaceutical industry is going through significant changes that are altering its business models, according to our analyst. This represents one of the new opportunities for market participants in the global pharmaceutical contract manufacturing organisations. According to our analysis, the pharmaceutical contract manufacturing organisations (CMOs) market is estimated to be valued at US$1,04,396 million in 2022 and is projected to reach a market value of US$2,03,240 million by 2032.
Growing Demand and Acceptability of Biosimilars Can Be Seen as a Big Opportunity for Pharma CMOs
Growing demand and acceptability of biosimilars can be seen as a big opportunity for contract manufacturing and research organisations. The requirement of affordable healthcare and upcoming patent expiries of innovative biologic drugs offers significant opportunities for biosimilars. Large pharma and biopharma companies see a huge opportunity in biosimilars. Rather than jump into the market on their own, most are interested in sharing their risks and working with collaborators. They are forming joint ventures or partnerships with the outsourcing providers. For Instance, in March 2022, Johnson & Johnson completed a historic agreement between Janssen Pharmaceuticals, Inc. and South African manufacturer Aspen SA Operations (Pty) Ltd to enable the first COVID-19 vaccine to be manufactured and made available by an African company for people living in Africa, with the goal of increasing COVID-19 vaccination rates across the continent.
What Questions Should You Ask before Buying a Market Research Report?
• How is the pharmaceutical contract manufacturing organisations (CMOs) market evolving?
• What is driving and restraining the pharmaceutical contract manufacturing organisations (CMOs) market?
• How will each pharmaceutical contract manufacturing organisations (CMOs) submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2032?
• What will be the main driver for the overall market from 2022 to 2032?
• Will leading pharmaceutical contract manufacturing organisations (CMOs) markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• Who are the leading players and what are their prospects over the forecast period?
• What are the pharmaceutical contract manufacturing organisations (CMOs) projects for these leading companies?
• How will the industry evolve during the period between 2022 and 2032? What are the implications of pharmaceutical contract manufacturing organisations (CMOs) projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the pharmaceutical contract manufacturing organisations (CMOs) market?
• Where is the pharmaceutical contract manufacturing organisations (CMOs) market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?
You need to discover how this will impact the pharmaceutical contract manufacturing organisations (CMOs) market today, and over the next 10 years:
• Our 370-page report provides 159 tables, 212 charts/graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them – NOW.
• It contains in-depth analysis of global, regional growth analysis.
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.
This report tells you TODAY how the top 50 pharmaceutical contract manufacturing organisations (CMOs) market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.
Forecasts to 2032 and other analyses reveal commercial prospects
• In addition to revenue forecasting to 2032, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), PEST Analysis, Porter’s Five Forces Analysis
This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regions
• North America
• Europe
• Asia Pacific
• South America
• Middle East and Africa
The report also includes profiles and for some of the leading companies in the Top 50 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market, 2022 to 2032, with a focus on this segment of these companies’ operations.
Leading companies and the potential for market growth
• Abbott Laboratories
• AbbVie Inc.
• Alkermes
• AstraZeneca
• Aurobindo Pharma
• Avid Bioservices, Inc.
• Bavarian Nordic
• Baxter Biopharma Solutions
• Bayer AG
• BD
• bioMérieux
• Boston Scientific Corporation
• CordenPharma International
• Catalent Inc.
• Consort Medical plc
• CSL Limited
• Divi's Laboratories Ltd.
• Dr. Reddy's Laboratories Ltd.
• Dupont
• Edwards Lifesciences Corporation
• Eli Lilly and Company
• Emergent BioSolutions
• Evonik Industries
• F. Hoffmann-La Roche Ltd.
• Fresenius SE&Co. KGaA
• Gilead Sciences, Inc.
• GSK plc
• Grifols
• Huapont Life Sciences Co Ltd.
• INOVIO Pharmaceuticals
• Johnson & Johnson Services Inc.
• Koninklijke DSM N.V. (Royal DSM)
• Lonza
• McKesson Corporation
• Merck KGaA
• Moderna Inc.
• Nipro Corporation
• Novartis AG
• Novavax
• Novo Nordisk A/S
• Pfizer Inc.
• PPD Inc.
• Sanofi
• Strides Pharma Science Limited
• Teva Pharmaceuticals Industries Ltd.
• Thermo Fisher Scientific Inc.
• UPM Pharmaceuticals
• VBI Vaccines Inc.
• WuXi AppTec
• ZHEJIANG HISUN PHARMACEUTICAL Co., LTD.
Overall world revenue for Pharmaceutical Contract Manufacturing Organisations (CMOs) Market, 2022 to 2032 in terms of value the market will surpass US$1,04,396 million in 2022, our work calculates. We predict strong revenue growth through to 2032. Our work identifies which organisations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How will the Top 50 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market Report 2022 report help you?
In summary, our 370-page report provides you with the following knowledge:
• Revenue forecasts to 2032 for Top 50 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market, 2022 to 2032 Market, with forecasts and company size, each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.
• Revenue forecasts to 2032 for five regional markets – See forecasts for the Top 50 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market, 2022 to 2032 market in North America, Europe, Asia-Pacific, South America, Middle East & Africa.
• Prospects for established firms and those seeking to enter the market – including company profiles for 50 of the major companies involved in the Top 50 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market, 2022 to 2032.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.
Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Our study is for everybody needing commercial analyses for the Top 50 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market, 2022 to 2032, market-leading companies. You will find data, trends and predictions.
'
1. Report Overview
1.1 Objectives of the Study
1.2 Introduction to Top 50 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered by This Analytical Report Include:
1.6 Who is This Report For?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Reports
1.10 About
2 Executive Summary
3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.2.1 Market Driving Factors
3.2.1.1 Biosimilars Are Becoming Increasingly Popular
3.2.1.2 Increased Concentration on Orphan and Specialty Drugs
3.2.1.3 Demand for Formulation Development Services is Growing
3.2.1.4 Biopharmaceutical Companies Strive for Strategic Collaboration with Drug Delivery Technology Firms
3.2.1.5 Continued Concentration on Productivity
3.2.1.6 Advantage of Cost Savings is Driving the Market Growth
3.2.1.7 To Mitigate Risk Associated to New Drug Development
3.2.2 Market Restraining Factors
3.2.2.1 Product and Process Development is a Challenge
3.2.2.2 The Main Challenge for the CMOs is to Attract Companies Ready to Invest
3.2.2.3 Stringent Regulations Are Hindering the Market Growth
3.2.2.4 Pharmaceutical Manufacturers Are Facing Big Revenue Challenges with the Patent Expirations
3.2.2.5 Challenge Related to the High R&D Expenditures
3.2.2.6 Backwards Compatibility for Generics Manufacturers
3.2.3 Market Opportunities
3.2.3.1 Manufacturing and Packaging Capabilities Are Lacking
3.2.3.2 Pharma Firms will Continue to Look for Ways to Reduce Drug Costs
3.2.3.3 New Drug Delivery Technologies Are Required
3.2.3.4 Chemical APIs Will See a Resurgence Following the Shift in Focus to Biological APIs
3.3 COVID-19 Impact Analysis
3.4 Porter’s Five Forces Analysis
3.4.1 Supplier Power
3.4.2 Buyer Power
3.4.3 Competitive Rivalry
3.4.4 Threat from Substitutes
3.4.5 Threat of New Entrants
3.5 PESTLE Analysis
3.5.1 Political
3.5.2 Economic
3.5.3 Social
3.5.4 Technological
3.5.5 Environmental
3.5.6 Legal
4 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market Analysis by Region
4.1 Key Findings
4.2 Regional Market Size Estimation and Forecast
5 Competitive Landscape
5.1 Company Share Analysis
5.2 Market Shares
5.2.1 Bulk Drugs and APIs
5.2.2 Solid Dosage Forms
5.2.3 Liquid Dosage Forms
5.2.3.1 Non-Sterile
5.2.3.2 Sterile
5.2.4 Semi-Solid Dosage Forms
6 Company Profiles
6.1 Johnson & Johnson Services Inc.
6.1.1 Company Snapshot
6.1.2 Company Overview
6.1.3 Financial Analysis
6.1.3.1 Net Revenue, 2017-2021
6.1.3.2 Operating Income, 2017-2021
6.1.3.3 Net Income, 2017-2021
6.1.3.4 EBITDA, 2017-2021
6.1.3.5 Company Regional Revenue Market Share
6.1.3.6 Company Business Segment Analysis
6.1.4 Service Benchmarking
6.1.5 Strategic Outlook
6.2 F. Hoffmann-La Roche Ltd.
6.2.1 Company Snapshot
6.2.2 Company Overview
6.2.3 Financial Analysis
6.2.3.1 Net Revenue, 2017-2021
6.2.3.2 Operating Income, 2017-2021
6.2.3.3 Net Income, 2017-2021
6.2.3.4 EBITDA, 2017-2021
6.2.3.5 Company Regional Revenue Market Share
6.2.3.6 Company Business Segment Analysis
6.2.4 Product Benchmarking
6.2.5 Strategic Outlook
6.3 Pfizer Inc.
6.3.1 Company Snapshot
6.3.2 Company Overview
6.3.3 Financial Analysis
6.3.3.1 Net Revenue, 2017-2021
6.3.3.2 Operating Income, 2017-2021
6.3.3.3 Net Income, 2017-2021
6.3.3.4 EBITDA, 2017-2021
6.3.3.5 Company Regional Revenue Market Share
6.3.4 Service Benchmarking
6.3.5 Strategic Outlook
6.4 Bayer AG
6.4.1 Company Snapshot
6.4.2 Company Overview
6.4.3 Financial Analysis
6.4.3.1 Net Revenue, 2017-2021
6.4.3.2 Operating Income, 2017-2021
6.4.3.3 Net Income, 2017-2021
6.4.3.4 EBITDA, 2017-2021
6.4.3.5 Company Regional Revenue Market Share
6.4.3.6 Company Business Segments Analysis
6.4.4 Product Benchmarking
6.4.5 Strategic Outlook
6.5 Novartis AG
6.5.1 Company Snapshot
6.5.2 Company Overview
6.5.3 Financial Analysis
6.5.3.1 Net Revenue, 2017-2021
6.5.3.2 Operating Income, 2017-2021
6.5.3.3 Net Income, 2017-2021
6.5.3.4 EBITDA, 2017-2021
6.5.3.5 Company Regional Revenue Market Share
6.5.3.6 Company Business Segments Analysis
6.5.4 Service Benchmarking
6.5.5 Strategic Outlook
6.6 CordenPharma International
6.6.1 Company Snapshot
6.6.2 Company Overview
6.6.3 Service Benchmarking
6.6.4 Strategic Outlook
6.7 GSK plc
6.7.1 Company Snapshot
6.7.2 Company Overview
6.7.3 Financial Analysis
6.7.3.1 Net Revenue, 2017-2021
6.7.3.2 Operating Income, 2017-2021
6.7.3.3 Net Income, 2017-2021
6.7.3.4 EBITDA, 2017-2021
6.7.3.5 Company Regional Revenue Market Share
6.7.3.6 Company Business Segments Analysis
6.7.4 Service Benchmarking
6.7.5 Strategic Outlook
6.8 Sanofi
6.8.1 Company Snapshot
6.8.2 Company Overview
6.8.3 Financial Analysis
6.8.3.1 Net Revenue, 2017-2021
6.8.3.2 Operating Income, 2017-2021
6.8.3.3 Net Income, 2017-2021
6.8.3.4 EBITDA, 2017-2021
6.8.3.5 Company Regional Revenue Market Share
6.8.3.6 Company Business Segments Analysis
6.8.4 Service Benchmarking
6.8.5 Strategic Outlook
6.9 AbbVie Inc.
6.9.1 Company Snapshot
6.9.2 Company Overview
6.9.3 Financial Analysis
6.9.3.1 Net Revenue, 2017-2021
6.9.3.2 Operating Income, 2017-2021
6.9.3.3 Net Income, 2017-2021
6.9.3.4 EBITDA, 2017-2021
6.9.3.5 Company Regional Revenue Market Share
6.9.3.6 Company Business Segments Analysis
6.9.4 Service Benchmarking
6.9.5 Strategic Outlook
6.10 Abbott Laboratories
6.10.1 Company Snapshot
6.10.2 Company Overview
6.10.3 Financial Analysis
6.10.3.1 Net Revenue, 2017-2021
6.10.3.2 Operating Income, 2017-2021
6.10.3.3 Net Income, 2017-2021
6.10.3.4 EBITDA, 2017-2021
6.10.3.5 Company Regional Revenue Market Share
6.10.3.6 Company Business Segments Analysis
6.10.4 Service Benchmarking
6.10.5 Strategic Outlook
6.11 Thermo Fisher Scientific Inc.
6.11.1 Company Snapshot
6.11.2 Company Overview
6.11.3 Financial Analysis
6.11.3.1 Net Revenue, 2017-2021
6.11.3.2 Operating Income, 2017-2021
6.11.3.3 Net Income, 2017-2021
6.11.3.4 EBITDA, 2017-2021
6.11.3.5 Company Regional Revenue Market Share
6.11.3.6 Company Business Segment Analysis
6.11.4 Service Benchmarking
6.11.5 Strategic Outlook
6.12 AstraZeneca
6.12.1 Company Snapshot
6.12.2 Company Overview
6.12.3 Financial Analysis
6.12.3.1 Net Revenue, 2017-2021
6.12.3.2 Operating Income, 2017-2021
6.12.3.3 Net Income, 2017-2021
6.12.3.4 EBITDA, 2017-2021
6.12.3.5 Company Regional Revenue Market Share
6.12.3.6 Company Business Segments Analysis
6.12.4 Service Benchmarking
6.12.5 Strategic Outlook
6.13 Eli Lilly and Company
6.13.1 Company Snapshot
6.13.2 Company Overview
6.13.3 Financial Analysis
6.13.3.1 Net Revenue, 2017-2021
6.13.3.2 Operating Income, 2017-2021
6.13.3.3 Net Income, 2017-2021
6.13.3.4 EBITDA, 2017-2021
6.13.3.5 Company Regional Revenue Market Share
6.13.3.6 Company Business Segments Analysis
6.13.4 Service Benchmarking
6.13.5 Strategic Outlook
6.14 Gilead Sciences, Inc.
6.14.1 Company Snapshot
6.14.2 Company Overview
6.14.3 Financial Analysis
6.14.3.1 Net Revenue, 2017-2021
6.14.3.2 Operating Income, 2017-2021
6.14.3.3 Net Income, 2017-2021
6.14.3.4 EBITDA, 2017-2021
6.14.4 Service Benchmarking
6.14.5 Strategic Outlook
6.15 DuPont
6.15.1 Company Snapshot
6.15.2 Company Overview
6.15.3 Financial Analysis
6.15.3.1 Net Revenue, 2017-2021
6.15.3.2 Operating Income, 2017-2021
6.15.3.3 Net Income, 2017-2021
6.15.3.4 EBITDA, 2017-2021
6.15.4 Service Benchmarking
6.15.5 Strategic Outlook
6.16 Novo Nordisk A/S
6.16.1 Company Snapshot
6.16.2 Company Overview
6.16.3 Financial Analysis
6.16.3.1 Net Revenue, 2017-2021
6.16.3.2 Operating Income, 2017-2021
6.16.3.3 Net Income, 2017-2021
6.16.3.4 EBITDA, 2017-2021
6.16.3.5 Company Regional Revenue Market Share
6.16.3.6 Company Business Segments Analysis
6.16.4 Service Benchmarking
6.16.5 Strategic Outlook
6.17 Merck KGaA
6.17.1 Company Snapshot
6.17.2 Company Overview
6.17.3 Financial Analysis
6.17.3.1 Net Revenue, 2017-2021
6.17.3.2 Operating Income, 2017-2021
6.17.3.3 Net Income, 2017-2021
6.17.3.4 EBITDA, 2017-2021
6.17.4 Service Benchmarking
6.17.5 Strategic Outlook
6.18 BD
6.18.1 Company Snapshot
6.18.2 Company Overview
6.18.3 Financial Analysis
6.18.3.1 Net Revenue, 2017-2021
6.18.3.2 Operating Income, 2017-2021
6.18.3.3 Net Income, 2017-2021
6.18.3.4 EBITDA, 2017-2021
6.18.3.5 Company Regional Revenue Market Share
6.18.3.6 Company Business Segments Analysis
6.18.4 Service Benchmarking
6.18.5 Strategic Outlook
6.19 Teva Pharmaceuticals Industries Ltd.
6.19.1 Company Snapshot
6.19.2 Company Overview
6.19.3 Financial Analysis
6.19.3.1 Net Revenue, 2017-2021
6.19.3.2 Operating Income, 2017-2021
6.19.3.3 Net Income, 2017-2021
6.19.3.4 EBITDA, 2017-2021
6.19.4 Service Benchmarking
6.19.5 Strategic Outlook
6.20 Evonik Industries
6.20.1 Company Snapshot
6.20.2 Company Overview
6.20.3 Service Benchmarking
6.20.4 Strategic Outlook
6.21 UPM Pharmaceuticals
6.21.1 Company Snapshot
6.21.2 Company Overview
6.21.3 Service Benchmarking
6.21.4 Strategic Outlook
6.22 Baxter Biopharma Solutions
6.22.1 Company Snapshot
6.22.2 Company Overview
6.22.3 Financial Analysis
6.22.3.1 Net Revenue, 2017-2021
6.22.3.2 Operating Income, 2017-2021
6.22.3.3 Net Income, 2017-2021
6.22.3.4 EBITDA, 2017-2021
6.22.3.5 Company Regional Revenue Market Share
6.22.3.6 Company Business Segments Analysis
6.22.4 Service Benchmarking
6.22.5 Strategic Outlook
6.23 Boston Scientific Corporation
6.23.1 Company Snapshot
6.23.2 Company Overview
6.23.3 Financial Analysis
6.23.3.1 Net Revenue, 2017-2021
6.23.3.2 Operating Income, 2017-2021
6.23.3.3 Net Income, 2017-2021
6.23.3.4 EBITDA, 2017-2021
6.23.3.5 Company Regional Revenue Market Share
6.23.3.6 Company Business Segments Analysis
6.23.4 Service Benchmarking
6.23.5 Strategic Outlook
6.24 Koninklijke DSM N.V. (Royal DSM)
6.24.1 Company Snapshot
6.24.2 Company Overview
6.24.3 Financial Analysis
6.24.3.1 Net Revenue, 2017-2021
6.24.3.2 Operating Income, 2017-2021
6.24.3.3 Net Income, 2017-2021
6.24.3.4 EBITDA, 2017-2021
6.24.4 Service Benchmarking
6.24.5 Strategic Outlook
6.25 CSL Limited
6.25.1 Company Snapshot
6.25.2 Company Overview
6.25.3 Financial Analysis
6.25.3.1 Net Revenue, 2017-2021
6.25.3.2 Operating Income, 2017-2021
6.25.3.3 Net Income, 2017-2021
6.25.3.4 EBITDA, 2017-2021
6.25.3.5 Company Regional Revenue Market Share
6.25.3.6 Company Business Segments Analysis
6.25.4 Service Benchmarking
6.25.5 Strategic Outlook
6.26 Lonza
6.26.1 Company Snapshot
6.26.2 Company Overview
6.26.3 Financial Analysis
6.26.3.1 Net Revenue, 2017-2021
6.26.3.2 Operating Income, 2017-2021
6.26.3.3 Net Income, 2017-2021
6.26.3.4 EBITDA, 2017-2021
6.26.3.5 Company Regional Revenue Market Share
6.26.3.6 Company Business Segments Analysis
6.26.4 Service Benchmarking
6.26.5 Strategic Outlook
6.27 McKesson Corporation
6.27.1 Company Snapshot
6.27.2 Company Overview
6.27.3 Financial Analysis
6.27.3.1 Net Revenue, 2017-2021
6.27.3.2 Operating Income, 2017-2021
6.27.3.3 Net Income, 2017-2021
6.27.3.4 EBITDA, 2017-2021
6.27.3.5 Company Regional Revenue Market Share
6.27.3.6 Company Business Segments Analysis
6.27.4 Product Benchmarking
6.27.5 Strategic Outlook
6.28 Edwards Lifesciences Corporation
6.28.1 Company Snapshot
6.28.2 Company Overview
6.28.3 Financial Analysis
6.28.3.1 Net Revenue, 2017-2021
6.28.3.2 Operating Income, 2017-2021
6.28.3.3 Net Income, 2017-2021
6.28.3.4 EBITDA, 2017-2021
6.28.3.5 Company Regional Revenue Market Share
6.28.3.6 Company Business Segments Analysis
6.28.4 Product Benchmarking
6.28.5 Strategic Outlook
6.29 Nipro Corporation
6.29.1 Company Snapshot
6.29.2 Company Overview
6.29.3 Service Benchmarking
6.29.4 Strategic Outlook
6.30 PPD Inc.
6.30.1 Company Snapshot
6.30.2 Company Overview
6.30.3 Service Benchmarking
6.30.4 Strategic Outlook
6.31 Grifols
6.31.1 Company Snapshot
6.31.2 Company Overview
6.31.3 Financial Analysis
6.31.3.1 Net Revenue, 2017-2021
6.31.3.2 Operating Income, 2017-2021
6.31.3.3 Net Income, 2017-2021
6.31.3.4 EBITDA, 2017-2021
6.31.4 Service Benchmarking
6.31.5 Strategic Outlook
6.32 bioMérieux
6.32.1 Company Snapshot
6.32.2 Company Overview
6.32.3 Financial Analysis
6.32.3.1 Net Revenue, 2017-2021
6.32.3.2 Operating Income, 2017-2021
6.32.3.3 Net Income, 2017-2021
6.32.3.4 EBITDA, 2017-2021
6.32.3.5 Company Regional Revenue Market Share
6.32.3.6 Company Business Segments Analysis
6.32.4 Product Benchmarking
6.32.5 Strategic Outlook
6.33 Aurobindo Pharma
6.33.1 Company Snapshot
6.33.2 Company Overview
6.33.3 Service Benchmarking
6.33.4 Strategic Outlook
6.34 Dr. Reddy's Laboratories Ltd.
6.34.1 Company Snapshot
6.34.2 Company Overview
6.34.3 Financial Analysis
6.34.3.1 Net Revenue, 2017-2021
6.34.3.2 Operating Income, 2017-2021
6.34.3.3 Net Income, 2017-2021
6.34.3.4 EBITDA, 2017-2021
6.34.3.5 Company Regional Revenue Market Share
6.34.3.6 Company Business Segments Analysis
6.34.4 Service Benchmarking
6.34.5 Strategic Outlook
6.35 WuXi AppTec
6.35.1 Company Snapshot
6.35.2 Company Overview
6.35.3 Service Benchmarking
6.35.4 Strategic Outlook
6.36 Huapont Life Sciences Co Ltd.
6.36.1 Company Snapshot
6.36.2 Company Overview
6.36.3 Service Benchmarking
6.37 ZHEJIANG HISUN PHARMACEUTICAL Co., LTD.
6.37.1 Company Snapshot
6.37.2 Company Overview
6.37.3 Service Benchmarking
6.37.4 Strategic Outlook
6.38 Alkermes
6.38.1 Company Snapshot
6.38.2 Company Overview
6.38.3 Financial Analysis
6.38.3.1 Net Revenue, 2017-2021
6.38.3.2 Operating Income, 2017-2021
6.38.3.3 Net Income, 2017-2021
6.38.3.4 EBITDA, 2017-2021
6.38.4 Service Benchmarking
6.38.5 Strategic Outlook
6.39 Emergent BioSolutions
6.39.1 Company Snapshot
6.39.2 Company Overview
6.39.3 Financial Analysis
6.39.3.1 Net Revenue, 2017-2021
6.39.3.2 Operating Income, 2017-2021
6.39.3.3 Net Income, 2017-2021
6.39.3.4 EBITDA, 2017-2021
6.39.4 Service Benchmarking
6.39.5 Strategic Outlook
6.40 Divi's Laboratories Limited
6.40.1 Company Snapshot
6.40.2 Company Overview
6.40.3 Service Benchmarking
6.41 Bavarian Nordic
6.41.1 Company Snapshot
6.41.2 Company Overview
6.41.3 Financial Analysis
6.41.3.1 Net Revenue, 2017-2021
6.41.3.2 Operating Income, 2017-2021
6.41.3.3 Net Income, 2017-2021
6.41.3.4 EBITDA, 2017-2021
6.41.3.5 Company Regional Revenue Market Share
6.41.3.6 Company Business Segments Analysis
6.41.4 Service Benchmarking
6.41.5 Strategic Outlook
6.42 Strides Pharma Science Limited
6.42.1 Company Snapshot
6.42.2 Company Overview
6.42.3 Service Benchmarking
6.42.4 Strategic Outlook
6.43 Consort Medical plc
6.43.1 Company Snapshot
6.43.2 Company Overview
6.43.3 Service Benchmarking
6.43.4 Strategic Outlook
6.44 Catalent Inc.
6.44.1 Company Snapshot
6.44.2 Company Overview
6.44.3 Financial Analysis
6.44.3.1 Net Revenue, 2017-2021
6.44.3.2 Operating Income, 2017-2021
6.44.3.3 Net Income, 2017-2021
6.44.3.4 EBITDA, 2017-2021
6.44.3.5 Company Regional Revenue Market Share
6.44.3.6 Company Business Segments Analysis
6.44.4 Service Benchmarking
6.44.5 Strategic Outlook
6.45 Moderna Inc.
6.45.1 Company Snapshot
6.45.2 Company Overview
6.45.3 Financial Analysis
6.45.3.1 Net Revenue, 2017-2021
6.45.3.2 Operating Income, 2017-2021
6.45.3.3 Net Income, 2017-2021
6.45.3.4 EBITDA, 2017-2021
6.45.4 Service Benchmarking
6.45.5 Strategic Outlook
6.46 Avid Bioservices, Inc.
6.46.1 Company Snapshot
6.46.2 Company Overview
6.46.3 Financial Analysis
6.46.3.1 Net Revenue, 2017-2021
6.46.3.2 Operating Income, 2017-2021
6.46.3.3 Net Income, 2017-2021
6.46.3.4 EBITDA, 2017-2021
6.46.4 Service Benchmarking
6.46.5 Strategic Outlook
6.47 Novavax
6.47.1 Company Snapshot
6.47.2 Company Overview
6.47.3 Financial Analysis
6.47.3.1 Net Revenue, 2017-2021
6.47.3.2 Operating Income, 2017-2021
6.47.3.3 Net Income, 2017-2021
6.47.3.4 EBITDA, 2017-2021
6.47.4 Service Benchmarking
6.47.5 Strategic Outlook
6.48 INOVIO Pharmaceuticals
6.48.1 Company Snapshot
6.48.2 Company Overview
6.48.3 Financial Analysis
6.48.3.1 Net Revenue, 2017-2021
6.48.3.2 Operating Income, 2017-2021
6.48.3.3 Net Income, 2017-2021
6.48.3.4 EBITDA, 2017-2021
6.48.4 Service Benchmarking
6.48.5 Strategic Outlook
6.49 VBI Vaccines Inc.
6.49.1 Company Snapshot
6.49.2 Company Overview
6.49.3 Financial Analysis
6.49.3.1 Net Revenue, 2017-2021
6.49.3.2 Operating Income, 2017-2021
6.49.3.3 Net Income, 2017-2021
6.49.3.4 EBITDA, 2017-2021
6.49.4 Service Benchmarking
6.49.5 Strategic Outlook
6.50 Fresenius SE&Co. KGaA
6.50.1 Company Snapshot
6.50.2 Company Overview
6.50.3 Financial Analysis
6.50.3.1 Net Revenue, 2017-2021
6.50.3.2 Operating Income, 2017-2021
6.50.3.3 Net Income, 2017-2021
6.50.3.4 EBITDA, 2017-2021
6.50.3.5 Company Regional Revenue Market Share
6.50.3.6 Company Business Segments Analysis
6.50.4 Service Benchmarking
6.50.5 Strategic Outlook
7 Conclusion and Recommendations
7.1 Concluding Remarks from
7.2 Recommendations for Market Players
7.2.4 Biopharma Manufacturing Demand Will Drive Growth 2022-2032
List of Tables
Table 1 Pharmaceutical Contract Manufacturing Market Snapshot, 2022 & 2032 (US$ billion, CAGR %)
Table 2 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market by Region, 2022-2032 (USD Bn, AGR (%), CAGR (%)) (V-Shaped Recovery Scenario)
Table 3 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market by Region, 2022 2032 (USD Bn, AGR (%), CAGR (%)) (U-Shaped Recovery Scenario)
Table 4 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market by Region, 2022-2032 (USD Bn, AGR (%), CAGR (%)) (W-Shaped Recovery Scenario)
Table 5 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market by Region, 2022-2032 (USD Bn, AGR (%), CAGR (%)) (L-Shaped Recovery Scenario)
Table 6 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market by Region, 2022-2032 (US$ mn, AGR (%))
Table 7 Market Share of Contract Manufacturing Companies Providing Bulk Drugs and APIs, 2021 (%)
Table 8 Market Share of Contract Manufacturing Companies Providing Solid Dosage Forms, 2021, (%)
Table 9 Market Share of Contract Manufacturing Companies Providing Nonsterile Liquid Dosage Forms, 2021 (%)
Table 10 Market Share of Contract Manufacturing Companies Providing Sterile Liquid Dosage Forms, 2021
Table 11 Market Share of Contract Manufacturing Companies Providing Sterile Liquid Dosage Forms, 2021
Table 12 Johnson & Johnson Services Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 13 Johnson & Johnson Services Inc.: Service Benchmarking
Table 14 Johnson & Johnson Services Inc.: Strategic Outlook
Table 15 F. Hoffmann-La Roche Ltd: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 16 F. Hoffmann-La Roche Ltd: Service Benchmarking
Table 17 F. Hoffmann-La Roche Ltd: Strategic Outlook
Table 18 Pfizer Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 19 Pfizer Inc.: Service Benchmarking
Table 20 Pfizer Inc.: Strategic Outlook
Table 21 Bayer AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 22 Bayer AG: Service Benchmarking
Table 23 Bayer AG: Strategic Outlook
Table 24 Novartis AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 25 Novartis AG: Service Benchmarking
Table 26 Novartis AG: Strategic Outlook
Table 27 CordenPharma International: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 28 CordenPharma International: Service Benchmarking
Table 29 CordenPharma International: Strategic Outlook
Table 30 GSK plc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 31 GSK plc: Service Benchmarking
Table 32 GSK plc: Strategic Outlook
Table 33 Sanofi: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 34 Sanofi: Service Benchmarking
Table 35 Sanofi: Strategic Outlook
Table 36 AbbVie Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 37 AbbVie Inc.: Service Benchmarking
Table 38 AbbVie Inc.: Strategic Outlook
Table 39 Abbott Laboratories: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 40 Abbott Laboratories: Service Benchmarking
Table 41 Abbott Laboratories: Strategic Outlook
Table 42 Thermo Fisher Scientific Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 43 Thermo Fisher Scientific Inc.: Service Benchmarking
Table 44 Thermo Fisher Scientific Inc.: Strategic Outlook
Table 45 AstraZeneca: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 46 AstraZeneca: Service Benchmarking
Table 47 AstraZeneca: Strategic Outlook
Table 48 Eli Lily and Company: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 49 Eli Lily and Company: Service Benchmarking
Table 50 Eli Lily and Company: Strategic Outlook
Table 51 Gilead Science Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 52 Gilead Science Inc.: Service Benchmarking
Table 53 Gilead Science Inc.: Strategic Outlook
Table 54 DuPont: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 55 DuPont: Service Benchmarking
Table 56 DuPont: Strategic Outlook
Table 57 Novo Nordisk A/S: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 58 Novo Nordisk A/S: Service Benchmarking
Table 59 Novo Nordisk A/S: Strategic Outlook
Table 60 Merck KGaA: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 61 Merck KGaA: Service Benchmarking
Table 62 Merck KGaA: Strategic Outlook
Table 63 BD: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 64 BD: Service Benchmarking
Table 65 BD: Strategic Outlook
Table 66 Teva Pharmaceutical: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 67 Teva Pharmaceutical: Service Benchmarking
Table 68 Teva Pharmaceutical: Strategic Outlook
Table 69 Evonik Industries: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 70 Evonik Industries: Service Benchmarking
Table 71 Evonik Industries: Strategic Outlook
Table 72 UPM Pharmaceuticals: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 73 UPM Pharmaceuticals: Service Benchmarking
Table 74 UPM Pharmaceuticals: Strategic Outlook
Table 75 Baxter Biopharma Solutions: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 76 Baxter Biopharma Solutions: Service Benchmarking
Table 77 Baxter Biopharma Solutions: Strategic Outlook
Table 78 Boston Scientific Corporation: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 79 Boston Scientific Corporation: Service Benchmarking
Table 80 Boston Scientific Corporation: Strategic Outlook
Table 81 Koninklijke DSM N.V: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 82 Koninklijke DSM N.V: Service Benchmarking
Table 83 Koninklijke DSM N.V: Strategic Outlook
Table 84 CSL Limited: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 85 CSL Limited: Service Benchmarking
Table 86 CSL Limited: Strategic Outlook
Table 87 Lonza: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 88 Lonza: Service Benchmarking
Table 89 Lonza: Strategic Outlook
Table 90 McKesson Corporation: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 91 McKesson Corporation: Service Benchmarking
Table 92 McKesson Corporation: Strategic Outlook
Table 93 Edwards Lifesciences: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 94 Edwards Lifesciences: Service Benchmarking
Table 95 Edwards Lifesciences: Strategic Outlook
Table 96 Nipro Corporation: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 97 Nipro Corporation: Service Benchmarking
Table 98 Nipro Corporation: Strategic Outlook
Table 99 PPD Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 100 PPD Inc.: Service Benchmarking
Table 101 PPD Inc.: Strategic Outlook
Table 102 Grifols: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 103 Grifols: Service Benchmarking
Table 104 Grifols: Strategic Outlook
Table 105 bioMérieux: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 106 Table 110 bioMérieux: Service Benchmarking
Table 107 bioMérieux: Strategic Outlook
Table 108 Aurobindo Pharma: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 109 Aurobindo Pharma: Service Benchmarking
Table 110 Aurobindo Pharma: Strategic Outlook
Table 111 Dr. Reddy's Laboratories Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 112 Dr. Reddy's Laboratories Ltd.: Service Benchmarking
Table 113 Dr. Reddy's Laboratories Ltd.: Strategic Outlook
Table 114 Wuxi AppTec: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 115 Wuxi AppTec: Service Benchmarking
Table 116 Wuxi AppTec: Strategic Outlook
Table 117 Huapont Life Sciences Co Ltd: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 118 Huapont Life Sciences Co Ltd: Service Benchmarking
Table 119 ZHEJIANG HISUN PHARMACEUTICAL Co., LTD.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 120 ZHEJIANG HISUN PHARMACEUTICAL Co., LTD.: Service Benchmarking
Table 121 ZHEJIANG HISUN PHARMACEUTICAL Co., LTD.: Strategic Outlook
Table 122 Alkermes: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 123 Alkermes: Service Benchmarking
Table 124 Alkermes: Strategic Outlook
Table 125 Emergent BioSolutions: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 126 Emergent BioSolutions: Service Benchmarking
Table 127 Emergent BioSolutions: Strategic Outlook
Table 128 Divi’s Laboratories Limited: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 129 Divi’s Laboratories Limited: Service Benchmarking
Table 130 Bavarian Nordic: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 131 Bavarian Nordic: Service Benchmarking
Table 132 Bavarian Nordic K: Strategic Outlook
Table 133 Strides Pharma Science Limited: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 134 Strides Pharma Science Ltd: Service Benchmarking
Table 135 Strides Pharma Science Limited: Strategic Outlook
Table 136 Consort Medical plc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 137 Consort Medical plc: Service Benchmarking
Table 138 Consort Medical plc: Strategic Outlook
Table 139 Catalent Inc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 140 Catalent Inc: Service Benchmarking
Table 141 Catalent Pharma Solutions Inc: Strategic Outlook
Table 142 Moderna Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 143 Moderna Inc.: Service Benchmarking
Table 144 Moderna Inc.: Strategic Outlook
Table 145 Avid Bioservices, Inc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 146 Avid Bioservices, Inc: Service Benchmarking
Table 147 Avid Bioservices, Inc: Strategic Outlook
Table 148 Novavax: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 149 Novavax: Service Benchmarking
Table 150 Novavax: Strategic Outlook
Table 151 INOVIO Pharmaceuticals: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 152 INOVIO Pharmaceuticals: Service Benchmarking
Table 153 INOVIO Pharmaceuticals: Strategic Outlook
Table 154 VBI Vaccines Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 155 VBI Vaccines Biotechnology: Service Benchmarking
Table 156 VBI Vaccines Biotechnology: Strategic Outlook
Table 157 Fresenius SE&Co. KGaA: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 158 Fresenius SE&Co. KGaA: Service Benchmarking
Table 159 Fresenius SE&Co. KGaA: Strategic Outlook
List of Figures
Figure 1 Pharmaceutical Contract Manufacturing Organisations (CMO): Market Dynamics
Figure 2 COVID Impact Analysis: Pharmaceutical Contract Manufacturing Organisations (CMOs) Market Recovery Scenarios
Figure 3 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market by Region, 2022-2032 (US$ mn, AGR (%)): “V” Shaped Recovery
Figure 4 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market by Region, 2022-2032 (US$ mn, AGR (%)): “U” Shaped Recovery
Figure 5 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market by Region, 2022-2032 (US$ mn, AGR (%)): “W” Shaped Recovery
Figure 6 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market by Region, 2022-2032 (US$ mn, AGR (%)): “L” Shaped Recovery
Figure 7 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market: Porter’s Five Forces Analysis
Figure 8 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market Forecast by Region 2022, 2027, 2032 (Revenue, CAGR%)
Figure 9 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market by Region, 2022-2032 (US$ mn, AGR (%))
Figure 10 Johnson & Johnson Services Inc.: Revenue, 2017-2021 (US$ million, AGR%)
Figure 11 Johnson & Johnson Services Inc.: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 12 Johnson & Johnson Services Inc.: Net Income 2017-2021 (US$ million, AGR%)
Figure 13 Johnson & Johnson Services Inc.: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 14 Johnson & Johnson Services Inc.: Company Regional Revenue Market Share Analysis 2021 (%)
Figure 15 Johnson & Johnson Services Inc.: Company Revenue Breakdown by Business Segments Analysis 2021 (%)
Figure 16 F. Hoffmann-La Roche Ltd: Revenue, 2017-2021 (US$ million, AGR%)
Figure 17 F. Hoffmann-La Roche Ltd: Operating Income 2017-2021 (US$ million, AGR%)
Figure 18 F. Hoffmann-La Roche Ltd: Net Income 2017-2021 (US$ million, AGR%)
Figure 19 F. Hoffmann-La Roche Ltd: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 20 F. Hoffmann-La Roche Ltd: Company Regional Revenue Market Share Analysis 2021 (%)
Figure 21 F. Hoffmann-La Roche Ltd: Company Revenue Breakdown by Business Segments Analysis, 2021 (%)
Source: Visiongain Reports Ltd., 2022
Figure 22 Pfizer Inc.: Revenue, 2017-2021 (US$ million, AGR%)
Figure 23 Pfizer Inc.: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 24 Pfizer Inc.: Net Income 2017-2021 (US$ million, AGR%)
Figure 25 Pfizer Inc.: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 26 Pfizer Inc.: Company Regional Revenue Market Share Analysis 2021 (%)
Figure 27 Bayer AG: Revenue, 2017-2021 (US$ million, AGR%)
Figure 28 Bayer AG: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 29 Bayer AG: Net Income 2017-2021 (US$ million, AGR%)
Figure 30 Bayer AG: EBITDA, 2017-2021 (US$million)
Figure 31 Bayer AG: Company Regional Revenue Market Share Analysis 2021(%)
Figure 32 Bayer AG: Company Revenue Breakdown by Business Segments Analysis, 2021 (%)
Figure 33 Novartis AG: Revenue, 2017-2021 (US$ million, AGR%)
Figure 34 Novartis AG: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 35 Novartis AG: Net Income 2017-2021 (US$ million, AGR%)
Figure 36 Novartis AG: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 37 Novartis AG: Company Regional Revenue Market Share Analysis 2021 (%)
Figure 38 Novartis AG: Company Revenue Breakdown by Business Segments Analysis 2021 (%)
Figure 39 GSK plc: Revenue, 2017-2021 (US$ million, AGR%)
Figure 40 GSK plc: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 41 GSK plc: Net Income 2017-2021 (US$ million, AGR%)
Figure 42 GSK plc: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 43 GSK plc: Company Regional Revenue Market Share Analysis 2021 (%)
Figure 44 GSK plc: Company Revenue Breakdown by Business Segments Analysis 2021 (%)
Figure 45 Sanofi: Revenue, 2017-2021 (US$ million, AGR%)
Figure 46 Sanofi: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 47 Sanofi: Net Income 2017-2021 (US$ million, AGR%)
Figure 48 Sanofi: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 49 Sanofi: Company Regional Revenue Market Share Analysis 2021 (%)
Figure 50 Sanofi: Company Revenue Breakdown by Business Segments Analysis 2021 (%)
Figure 51 AbbVie Inc.: Revenue, 2017-2021 (US$ million, AGR%)
Figure 52 AbbVie Inc.: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 53 AbbVie Inc.: Net Income 2017-2021 (US$ million, AGR%)
Figure 54 AbbVie Inc.: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 55 AbbVie Inc.: Company Regional Revenue Market Share Analysis 2021 (%)
Figure 56 AbbVie Inc.: Company Revenue Breakdown by Business Segments Analysis 2021 (%)
Figure 57 Abbott Laboratories: Revenue, 2017-2021 (US$ million, AGR%)
Figure 58 Abbott Laboratories: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 59 Abbott Laboratories: Net Income 2017-2021 (US$ million, AGR%)
Figure 60 Abbott Laboratories: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 61 Abbott Laboratories: Company Regional Revenue Market Share Analysis 2021(%)
Figure 62 Abbott Laboratories: Company Revenue Breakdown by Business Segments Analysis 2021 (%)
Figure 63 Thermo Fisher Scientific Inc.: Revenue, 2017-2021 (US$ million, AGR%)
Figure 64 Thermo Fisher Scientific Inc.: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 65 Thermo Fisher Scientific Inc.: Net Income 2017-2021 (US$ million, AGR%)
Figure 66 Thermo Fisher Scientific Inc.: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 67 Thermo Fisher Scientific Inc.: Company Regional Revenue Market Share Analysis 2021 (%)
Figure 68 Thermo Fisher Scientific Inc.: Company Revenue Breakdown by Business Segments Analysis 2021 (%)
Figure 69 AstraZeneca: Revenue, 2017-2021 (US$ million, AGR%)
Figure 70 AstraZeneca: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 71 AstraZeneca: Net Income 2017-2021 (US$ million, AGR%)
Figure 72 AstraZeneca: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 73 AstraZeneca: Company Regional Revenue Market Share Analysis 2021 (%)
Figure 74 AstraZeneca: Company Revenue Breakdown by Business Segments Analysis 2021 (%)
Figure 75 Eli Lily and Company: Revenue, 2017-2021 (US$ million, AGR%)
Figure 76 Eli Lily and Company: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 77 Eli Lily and Company: Net Income 2017-2021 (US$ million, AGR%)
Figure 78 Eli Lily and Company: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 79 Eli Lily and Company: Company Regional Revenue Market Share Analysis 2021 (%)
Figure 80 Eli Lily and Company: Company Revenue Breakdown by Business Segments Analysis 2021(%)
Figure 81 Gilead Science Inc.: Revenue, 2017-2021 (US$ million, AGR%)
Figure 82 Gilead Science Inc.: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 83 Gilead Science Inc.: Net Income 2017-2021 (US$ million, AGR%)
Figure 84 Gilead Science Inc.: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 85 DuPont: Revenue, 2017-2021 (US$ million, AGR%)
Figure 86 DuPont: Operating Income, 2017-2021 (US$ million)
Figure 87 DuPont: Net Income 2017-2021 (US$ million)
Figure 88 DuPont: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 89 Novo Nordisk A/S: Revenue, 2017-2021 (US$ million, AGR%)
Figure 90 Novo Nordisk A/S: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 91 Novo Nordisk A/S: Net Income 2017-2021 (US$ million, AGR%)
Figure 92 Novo Nordisk A/S: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 93 Novo Nordisk A/S: Company Regional Revenue Market Share Analysis 2021 (%)
Figure 94 Novo Nordisk A/S: Company Revenue Breakdown by Business Segments Analysis 2021 (%)
Figure 95 Merck KGaA: Revenue, 2017-2021 (US$ million, AGR%)
Figure 96 Merck KGaA: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 97 Merck KGaA: Net Income 2017-2021 (US$ million, AGR%)
Figure 98 Merck KGaA: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 99 Merck KGaA: Company Regional Revenue Market Share Analysis 2021 (%)
Figure 100 Merck KGaA: Company Revenue Breakdown by Business Segments Analysis 2021 (%)
Figure 101 BD: Revenue, 2017-2021 (US$ million, AGR%)
Figure 102 BD: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 103 BD: Net Income 2017-2021 (US$ million, AGR%)
Figure 104 BD: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 105 BD: Regional Revenue Market Share Analysis 2021 (%)
Figure 106 BD: Revenue Breakdown by Business Segments Analysis 2021 (%)
Figure 107 Teva Pharmaceutical: Revenue, 2017-2021 (US$ million, AGR%)
Figure 108 Teva Pharmaceutical: Operating Income, 2017-2021 (US$ million)
Figure 109 Teva Pharmaceutical: Net Income 2017-2021 (US$ million)
Figure 110 Teva Pharmaceutical: EBITDA, 2017-2021 (US$ million)
Figure 111 Baxter Biopharma Solutions: Revenue, 2017-2021 (US$ million, AGR%)
Figure 112 Baxter Biopharma Solutions: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 113 Baxter Biopharma Solutions: Net Income 2017-2021 (US$ million, AGR%)
Figure 114 Baxter Biopharma Solutions: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 115 Baxter Biopharma Solutions: Company Regional Revenue Market Share Analysis 2021 (%)
Figure 116 Baxter Biopharma Solutions: Company Revenue Breakdown by Business Segments Analysis 2021 (%)
Figure 117 Boston Scientific Corporation: Revenue, 2017-2021 (US$ million, AGR%)
Figure 118 Boston Scientific Corporation: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 119 Boston Scientific Corporation: Net Income 2017-2021 (US$ million)
Figure 120 Boston Scientific Corporation: EBITDA, 2017-2021 (US$ million)
Figure 121 Boston Scientific Corporation: Company Regional Revenue Market Share Analysis 2021(US$Mn)
Figure 122 Boston Scientific Corporation: Company Revenue Breakdown by Business Segments Analysis 2021 (%)
Figure 123 Koninklijke DSM N.V: Revenue, 2017-2021 (US$ million, AGR%)
Figure 124 Koninklijke DSM N.V: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 125 Koninklijke DSM N.V: Net Income 2017-2021 (US$ million, AGR%)
Figure 126 Koninklijke DSM N.V: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 127 CSL Limited: Revenue, 2017-2021 (US$ million, AGR%)
Figure 128 CSL Limited: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 129 CSL Limited: Net Income 2017-2021 (US$ million, AGR%)
Figure 130 CSL Limited: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 131 CSL Limited: Company Regional Revenue Market Share Analysis 2021 (%)
Figure 132 CSL Limited: Company Revenue Breakdown by Business Segments Analysis 2021 (%)
Figure 133 Lonza: Revenue, 2017-2021 (US$ million, AGR%)
Figure 134 Lonza: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 135 Lonza: Net Income 2017-2021 (US$ million, AGR%)
Figure 136 Lonza: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 137 Lonza: Company Regional Revenue Market Share Analysis 2021 (%)
Figure 138 Lonza Company Revenue Breakdown by Business Segments Analysis, 2021 (%)
Figure 139 McKesson Corporation: Revenue, 2017-2021 (US$ million, AGR%)
Figure 140 McKesson Corporation: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 141 McKesson Corporation: Net Income 2017-2021 (US$ million, AGR%)
Figure 142 McKesson Corporation: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 143 McKesson Corporation: Company Regional Revenue Market Share Analysis 2021 (%)
Figure 144 McKesson Corporation: Company Revenue Breakdown by Business Segments Analysis 2021 (%)
Figure 145 Edwards Lifesciences: Revenue, 2017-2021 (US$ million, AGR%)
Figure 146 Edwards Lifesciences: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 147 Edwards Lifesciences: Net Income 2017-2021 (US$ million, AGR%)
Figure 148 Edwards Lifesciences: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 149 Edwards Lifesciences: Company Regional Revenue Market Share Analysis 2021 (%)
Figure 150 Edwards Lifesciences: Company Revenue Breakdown by Business Segments Analysis, 2021 (%)
Figure 151 Grifols: Revenue, 2017-2021 (US$ million, AGR%)
Figure 152 Grifols: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 153 Grifols: Net Income 2017-2021 (US$ million, AGR%)
Figure 154 Grifols: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 155 bioMérieux: Revenue, 2017-2021 (US$ million, AGR%)
Figure 156 bioMérieux: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 157 bioMérieux: Net Income 2017-2021 (US$ million, AGR%)
Figure 158 bioMérieux: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 159 bioMérieux: Company Regional Revenue Market Share Analysis 2021 (%)
Figure 160 bioMérieux: Company Revenue Breakdown by Business Segments Analysis, 2021 (%)
Figure 161 Dr. Reddy's Laboratories Ltd.: Revenue, 2017-2021 (US$ million, AGR%)
Figure 162 Dr. Reddy's Laboratories Ltd.: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 163 Dr. Reddy's Laboratories Ltd.: Net Income 2017-2021 (US$ million, AGR%)
Figure 164 Dr. Reddy's Laboratories Ltd.: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 165 Dr. Reddy's Laboratories Ltd.: Company Regional Revenue Market Share Analysis 2021 (%)
Figure 166 Dr. Reddy's Laboratories Ltd. Company Revenue Breakdown by Business Segments Analysis, 2021 (%)
Figure 167 Alkermes: Revenue, 2017-2021 (US$ million, AGR%)
Figure 168 Alkermes: Operating Income, 2017-2021 (US$ million)
Figure 169 Alkermes: Net Income 2017-2021 (US$ million)
Figure 170 Alkermes: EBITDA, 2017-2021 (US$ million)
Figure 171 Emergent BioSolutions: Revenue, 2017-2021 (US$ million, AGR%)
Figure 172 Emergent BioSolutions: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 173 Emergent BioSolutions: Net Income 2017-2021 (US$ million, AGR%)
Figure 174 Emergent BioSolutions: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 175 Bavarian Nordic: Revenue, 2017-2021 (US$ million, AGR%)
Figure 176 Bavarian Nordic: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 177 Bavarian Nordic: Net Income 2017-2021 (US$ million, AGR%)
Figure 178 Bavarian Nordic: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 179 Bavarian Nordic: Company Regional Revenue Market Share Analysis 2021 (%)
Figure 180 Bavarian Nordic: Company Revenue Breakdown by Business Segments Analysis, 2021 (%)
Figure 181 Catalent Inc: Revenue, 2017-2021 (US$ million, AGR%)
Figure 182 Catalent Inc: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 183 Catalent Inc: Net Income 2017-2021 (US$ million, AGR%)
Figure 184 Catalent Inc: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 185 Catalent Inc: Company Regional Revenue Market Share Analysis 2021 (%)
Figure 186 Catalent Inc: Company Revenue Breakdown by Business Segments Analysis, 2021 (%)
Figure 187 Moderna Inc.: Revenue, 2017-2021 (US$ million, AGR%)
Figure 188 Moderna Inc.: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 189 Moderna Inc.: Net Income 2017-2021 (US$ million, AGR%)
Figure 190 Moderna Inc.: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 191 Avid Bioservices, Inc: Revenue, 2017-2021 (US$ million, AGR%)
Figure 192 Avid Bioservices, Inc: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 193 Avid Bioservices, Inc: Net Income 2017-2021 (US$ million, AGR%)
Figure 194 Avid Bioservices, Inc: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 195 Novavax: Revenue, 2017-2021 (US$ million, AGR%)
Figure 196 Novavax Operating Income, 2017-2021 (US$ million)
Figure 197 Novavax: Net Income 2017-2021 (US$ million)
Figure 198 Novavax: EBITDA, 2017-2021 (US$ million)
Figure 199 INOVIO Pharmaceuticals: Revenue, 2017-2021 (US$ million, AGR%)
Figure 200 INOVIO Pharmaceuticals: Operating Income, 2017-2021 (US$ million)
Figure 201 INOVIO Pharmaceuticals: Net Income 2017-2021 (US$ million)
Figure 202 INOVIO Pharmaceuticals: EBITDA, 2017-2021 (US$ million)
Figure 203 VBI Vaccines Inc.: Revenue, 2017-2021 (US$ million)
Figure 204 VBI Vaccines Inc.: Operating Income, 2017-2021 (US$ million)
Figure 205 VBI Vaccines Inc.: Net Income 2017-2021 (US$ million, AGR%)
Figure 206 VBI Vaccines Inc.: EBITDA, 2017-2021 (US$ million)
Figure 207 Fresenius SE&Co. KGaA: Revenue, 2017-2021 (US$ million, AGR%)
Figure 208 Fresenius SE&Co. KGaA: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 209 Fresenius SE&Co. KGaA: Net Income 2017-2021 (US$ million, AGR%)
Figure 210 Fresenius SE&Co. KGaA: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 211 Fresenius SE&Co. KGaA: Regional Market Share 2021 (%)
Figure 212 Fresenius SE&Co. KGaA: Business Segment Share (%), 2021
